- Cellectar Biosciences secures a 10-year supply agreement with NorthStar for non-carrier added Ac-225.
- The agreement will support Cellectar’s CLR 121225 radiotherapy program targeting solid tumours.
Cellectar Biosciences has announced a decade-long supply agreement with NorthStar Medical Radioisotopes for the supply of non-carrier added (n.c.a.) Actinium-225 (Ac-225), a key radioisotope in cancer treatment. This agreement is set to provide Cellectar with a stable Ac-225 supply, enabling it to progress its CLR 121225 program, which targets solid tumours, into clinical trials by 2025.
Actinium-225, a rare and high-demand radioisotope, plays a critical role in targeted radiotherapies but is often in short supply. With this agreement, NorthStar will ensure that Cellectar has consistent access to Ac-225 for its targeted alpha therapy (TAT) program, which has shown preclinical promise in treating pancreatic, triple-negative breast, and other solid tumours. Cellectar’s proprietary Phospholipid Ether (PLE) delivery platform will facilitate targeted delivery of Ac-225 to tumour cells.
James Caruso, president and CEO of Cellectar, noted, “This agreement with NorthStar provides a reliable source of Ac-225, which is critical to our clinical development strategy. Our PLE platform is uniquely positioned to optimise delivery for specific tumour types, and we are eager to advance CLR 121225 into human trials next year.”
NorthStar, known for its work in radiopharmaceutical production, is committed to supplying high-purity Ac-225 to support growing interest in radiotherapies. “Our passion is to reduce technological and operational barriers to give companies like Cellectar a reliable source of environmentally preferred, high-purity Ac-225 that will help make these new therapies possible,” said Frank Scholz, NorthStar’s president and CEO.
Overview of outsourcing trends 
